Canakinumab MAP in COVID-19 Pneumonia With CRS

Summary

This is a global Managed Access Program (MAP) to provide access to canakinumab to patients with cytokine release syndrome resulting from COVID-19 pneumonia

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications